January 25, 2018
GenSight Biologics reports €55 million 2017 year-end cash position and provides corporate update
Media
January 25, 2018
Cash position and activity update for Q4 2017
January 25, 2018
Onxeo receives EPO Intent-to-Grant Notice for key AsiDNA™ patent, extending IP protection in Europe until 2031
January 25, 2018
Strongbridge Biopharma plc Announces Pricing of Public Offering of Ordinary Shares
January 23, 2018
Altimmune Announces Notice of Allowance on Patent Covering Use of NasoShield in the U.S.
January 23, 2018
Onxeo Provides Update on Litigation with SpeBio/SpePharm
January 23, 2018
Nexstim Plc receives R&D loan from Business Finland
January 23, 2018
Emil Billbäck appointed CEO of BONESUPPORT
January 23, 2018
Strongbridge Biopharma plc Announces Proposed Public Offering of 5 Million Ordinary Shares
January 22, 2018
PUBLICATION HIGHLIGHTS A NOVEL CERAMENT® CARRIER WITH BONE ACTIVE AGENTS ENHANCING BONE FORMATION
